Establishment of Radiomics Database by Clinical Application of Multiparametric MRI Based on Incoherent Undersampling

Study Overview
=================
Brief Summary
-----------------
This study aims to establish radiomics database for pancreas cancer from multiparametric MRI including DCE-MRI obtained by using incoherent undersampling and radial acquisition for clinical staging as well as quantitative analysis.

Official Title
-----------------
Establishment of Radiomics Database by Clinical Application of Multiparametric MRI Including DCE-MRI Based on Incoherent Undersampling

Conditions
-----------------
Pancreas Cancer

Intervention / Treatment
-----------------
* Procedure: multi-parametric MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: surgical candidate for pancreatico-duodenectomy characteristic finding of pancreatic adenocarcinoma on prior CT or MRI OR histologically diagnosed with pancreatic adenocarcinoma signed for informed consent Exclusion Criteria: under 18 years not eligible for pancreatico-duodenectomy unresectable patients (locally advanced on prior CT/MRI or metastatic disease) tumors with suspicion of other histologic types (neuroendocrine, IPMN, etc) any contra-indication of contrast-enhanced MRI recurred pancreatic cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: multi-parametric MRI|multiparametric MRI is performed in all patients, and the sequence includes dynamic contrast enhanced (DCE) MRI, diffusion weighted imaging (DWI), tissue maps, and MR cholangiography.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| T-staging | T-staging of the tumor at MRI. | 4 weeks after MR acquisition | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| N-staging | N-staging of the tumor at MRI | 4 weeks after MR acquisition | 
| arterial blood flow | arterial blood flow of the tumor and adjacent parenchma on DCE-MRI | 4 weeks after MR acquisition | 
| arterial fraction | arterial fraction of the tumor and adjacent parenchyma on DCE-MRI | 4 weeks after MR acquisition | 
| mean transit time | mean transit time of the tumor and adjacent parenchyma on DCE-MRI | 4 weeks after MR acquisition | 
| extracellular volume | extracellular volume of the tumor and adjacent parenchyma on DCE-MRI | 4 weeks after MR acquisition | 
| true diffusion | true diffusion of the tumor and adjacent parenchyma on DWI with intravoxel incoherent motion model | 4 weeks after MR acquisition | 
| pseudodiffusion | pseudodiffusion of the tumor and adjacent parenchyma on DWI with intravoxel incoherent motion model | 4 weeks after MR acquisition | 
| perfusion fraction | perfusion fraction of the tumor and adjacent parenchyma on DWI with intravoxel incoherent motion model | 4 weeks after MR acquisition | 
| kurtosis | kurtosis of the tumor and adjacent parenchyma on DWI with kurtosis model | 4 weeks after MR acquisition | 
| mean diffusivity | mean diffusivity of the tumor and adjacent parenchyma on DWI with kurtosis model | 4 weeks after MR acquisition | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MRI